1. Home
  2. RVI vs ZVRA Comparison

RVI vs ZVRA Comparison

Compare RVI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robinhood Ventures Fund I Common Shares of Beneficial Interest

RVI

Robinhood Ventures Fund I Common Shares of Beneficial Interest

SELL

Current Price

$25.65

Market Cap

778.2M

Sector

N/A

ML Signal

SELL

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

SELL

Current Price

$10.27

Market Cap

689.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RVI
ZVRA
Founded
N/A
2006
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
778.2M
689.4M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
RVI
ZVRA
Price
$25.65
$10.27
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $25.00
AVG Volume (30 Days)
128.6K
★ 871.3K
Earning Date
N/A
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 159.21
EPS
N/A
★ 0.74
Revenue
N/A
★ $106,470,000.00
Revenue This Year
N/A
$43.97
Revenue Next Year
N/A
$15.93
P/E Ratio
★ N/A
$13.82
Revenue Growth
N/A
★ 350.91
52 Week Low
$22.21
$8.01
52 Week High
$77.39
$15.04

Technical Indicators

Market Signals
Indicator
RVI
ZVRA
Relative Strength Index (RSI) 39.73 38.24
Support Level $24.29 $10.07
Resistance Level $29.49 $11.07
Average True Range (ATR) 0.86 0.52
MACD -0.21 -0.05
Stochastic Oscillator 33.04 25.08

Price Performance

Historical Comparison
RVI
ZVRA

About RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest

Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: